Monotypic plasma cells in labial salivary glands of patients with Sjögren’s syndrome: Prognosticator for systemic lymphoproliferative disease

C Bodeutsch, P C M de Wilde, L Kater, F H J van den Hoogen, R J Hené, J C van Houwelingen, L B A van de Putte, G P Vooijs

Abstract

Aims: To determine the prevalence of plasma cell monotypia in labial salivary gland tissue of patients with and without Sjögren’s syndrome, and to evaluate its relation to the development of systemic monoclonal lymphoproliferative disorders.

Methods: A quantitative immunohistological study was performed on labial salivary gland tissue of 45 patients with Sjögren’s syndrome, 18 with rheumatoid arthritis without Sjögren’s syndrome, and 80 healthy controls. In none of the patients with Sjögren’s syndrome was there evidence of systemic monoclonal lymphoproliferative disease at the time of biopsy.

Results: Monotypic plasma cell populations, defined by a $k$:$\lambda$ ratio of $\geq 3$, were only observed in older patients (above 43 years) with Sjögren’s syndrome. In almost all these patients monotypic plasma cell populations were present in multiple labial salivary gland tissues and the IgM/\(k\) monotypia was observed most frequently. The prevalence of monotypic plasma cell populations in the group with Sjögren’s syndrome was 22% (10/45) and there was no significant predilection for primary Sjögren’s syndrome. Of special clinical interest was the observation that progression to systemic monoclonal lymphoproliferative disease had occurred exclusively in this subgroup of patients with Sjögren’s syndrome, with a prevalence of 30% (3/10).

Conclusion: Quantitative immunohistological examination of labial salivary gland tissues provides pathologists with a simple method to select those patients with Sjögren’s syndrome who have an increased relative risk at the time of biopsy to develop benign or malignant lymphoproliferative disorders.

Sjögren’s syndrome has often been regarded as a link in the spectrum between autoimmune disease and lymphoproliferative disorders.\(^1\)\(^2\)\(^3\)

Polyclonal B cell activation, characterised by hypergammaglobulinemia and autoimmune formation, such as rheumatoid factors, antinuclear antibodies, and antibodies to Ro/SS-A and La/SS-B, is a common finding in Sjögren’s syndrome.\(^2\)\(^3\) It is well known that benign or malignant systemic monoclonal gammopathy, or malignant lymphoma, may evolve from a polyclonal lymphoproliferative process in Sjögren’s syndrome.\(^2\)\(^3\)\(^4\)\(^5\) An epidemiological study has shown that the relative risk of developing malignant lymphoma in Sjögren’s syndrome is about 44 times higher than in the normal population.\(^6\) In this study the risk of malignant lymphoma was similar for primary Sjögren’s syndrome and secondary Sjögren’s syndrome, although other investigators believe malignant lymphoma to be more common in primary Sjögren’s syndrome.\(^6\)

Although a sudden decrease in serum immunoglobulin concentration has been recognised as a portent of malignant transformation,\(^7\)\(^8\)\(^9\) when Sjögren’s syndrome is diagnosed it is not possible to detect patients prone to such a transformation.

Much more promising with regard to predicting malignant transformation in such patients were the observations that extra-salivary gland non-Hodgkin’s lymphomas occurred exclusively in patients with Sjögren’s syndrome and a myoepithelial saliadenitis of the major salivary glands with monotypic B cell proliferation areas, but not in those with polytypic B cell proliferation areas.\(^10\)\(^11\)\(^12\) However, these very interesting findings are of relatively little clinical importance, as the labial salivary gland tissue biopsy specimen is much more widely used to diagnose Sjögren’s syndrome than the major salivary gland biopsy specimen.

In a recent study monoclonal plasma cell populations, defined by a $k$:$\lambda$ ratio of $\geq 3$ have been demonstrated in labial salivary gland tissues of more than 50% of patients with Sjögren’s syndrome with concomitant monoclonal cryoglobulinemia.\(^13\)

However, findings from systematic studies on the prevalence of monotypic plasma cell populations in the labial salivary gland tissues of patients with Sjögren’s syndrome without systemic monoclonal lymphoproliferative disorders at the time of biopsy, and their association with progression into the latter disorders, have never been published.

Methods

Labial salivary gland tissue biopsy specimens from 143 subjects were used (table 1). Group I comprised 80 healthy control subjects free of systemic diseases, who underwent intraoral surgery for cosmetic or preprosthetic purposes;
Table 1 Clinical details of subjects studied

<table>
<thead>
<tr>
<th>Group (mean age, range)</th>
<th>n</th>
<th>Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>I (37-7 years 0-78 years)</td>
<td>80</td>
<td>Healthy controls: intraoral surgery for cosmetic or preprosthetic purposes; no evidence of systemic disease. Rheumatoid arthritis: volunteers without subjective ocular or oral dryness, or salivary gland swellings, clinically not suspected of having Sjögren's syndrome.</td>
</tr>
<tr>
<td>II (58-6 years 42-78 years)</td>
<td>18</td>
<td>Sjögren's syndrome: keratoconjunctivitis sicca*, focal lymphocytic adenitis of the labial salivary glands with a lymphocytic focus score of &gt; 1 and serological abnormalities. †</td>
</tr>
<tr>
<td>III (50-5 years 14-76 years)</td>
<td>45</td>
<td>Sjögren's syndrome: keratoconjunctivitis sicca*, focal lymphocytic adenitis of the labial salivary glands with a lymphocytic focus score of &gt; 1 and serological abnormalities. †</td>
</tr>
</tbody>
</table>

*Examination through slit lamp and at least two tests positive for the following: Schirmer's test < 5 mm/min, van Bijlsma's score of > 3, tear break up time of < 10 seconds, decreased tear lysozyme or lactoferrin concentration. In five patients only Schirmer's test was performed. † Increase in serum IgA, serum IgG, or serum IgM, and/or presence of autoantibodies (rheumatoid factor and/or antinuclear antibody and/or anti-SS-A and/or anti-SS-B). |

Table 2 Immunoperoxidase procedures used

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Dewaxing and rehydration</td>
</tr>
<tr>
<td>2</td>
<td>Removing of mercury pigment by immersion in Lugol's iodine (5 min)</td>
</tr>
<tr>
<td>3</td>
<td>Blocking of endogenous peroxidase in methanol containing 1% hydrogen peroxide (30 min)</td>
</tr>
<tr>
<td>4</td>
<td>Preincubation with normal swine serum (20 min)</td>
</tr>
<tr>
<td>5</td>
<td>Incubation with diluted monoclonal antisera against IgA (1 in 800), IgG (1 in 200), IgM (1 in 800), IgA (1 in 2400) and IgG (1 in 2400) (1 hour)</td>
</tr>
<tr>
<td>6</td>
<td>Incubation with diluted swine anti-rabbit serum (1 in 20) (30 min)</td>
</tr>
<tr>
<td>7</td>
<td>Incubation with diluted rabbit PAP PAP complex (1 in 800) (20 min)</td>
</tr>
<tr>
<td>8</td>
<td>Development of peroxidase with diaminobenzidine and hydrogen peroxide (5 min), intensified with CuSO4 (1 min)</td>
</tr>
<tr>
<td>9</td>
<td>Counterstain with Mayer's haematoxylin, dehydrate, and mount in DPX</td>
</tr>
</tbody>
</table>

Antiserum diluted in phosphate buffered saline (pH 7.4) containing 1% bovine serum albumin; optimal dilutions found by chess board titration; incubations at room temperature. All antisera were purchased from Dakopatts, Denmark. Specificity of all antisera was confirmed by appropriate laboratory tests and on monoclonal plasma cells in bone marrow biopsy specimens obtained from related patients with myeloma.

group II comprised 18 patients with rheumatoid arthritis (RA) without sicca disorders, who were willing to undergo a lip biopsy. Both served as control groups. Group III consisted of 45 patients with Sjögren's syndrome, 35 with primary Sjögren's syndrome, and 10 with secondary Sjögren's syndrome. All patients with RA fulfilled the criteria defined by the American Rheumatism Association. The diagnosis of Sjögren's syndrome was based on the presence of ophthalmologically confirmed keratoconjunctivitis sicca,* and a grade IV focal sialoadenitis was based on the scale of Chisholm and Mason,* corresponding with a lymphocytic focus score of more than one lymphocytic focus per 4 mm² labial salivary gland tissue. More relevant clinical information about the patients is given in table 1.

All labial salivary gland tissue biopsy specimens were obtained using the horizontal incision technique described by Greenspan et al.† Informed consent was obtained. None of the subjects had evidence of a systemic benign or malignant monoclonal disorder or malignant lymphoma at the time of labial salivary gland tissue biopsy.

All biopsy specimens were fixed in a formal sublimate solution* † and embedded in paraffin wax. Histological examination and lymphocytic focus scoring were performed on haematoxylin and eosin stained sections. In addition, serial 5 μm sections were stained with a peroxidase-antiperoxidase diaminobenzidine (PAP/DAB) technique to visualise IgA, IgG, IgM, κ, and λ containing plasma cells. Technical details of the PAP/DAB technique are summarised in table 2. In cases where monoclonicity of the plasma cellular infiltrate was suspected on the basis of the immunoperoxidase staining results, double immunofluorescence labelling with antibodies against heavy and light chains (IgA/κ, IgA/λ, IgG/κ, IgG/λ, IgM/κ, and IgM/λ) was performed on 5 μm serial paraffin wax sections.

The following five quantitative immunohistological parameters were obtained from measurements in 30 to 40 systematically sampled test fields of 0-04 μm²: the mean numbers of IgA, IgG, IgM, κ, and λ containing plasma cells per 0-04 mm² labial salivary gland tissue. From these parameters the percentages of IgA, IgG, IgM, and κ containing plasma were calculated and will be further designated %IgA, %IgG, %IgM, and %κ. The procedure for quantification of positive plasma cells and tissue sampling has been described in detail elsewhere.

The following serological tests were performed on patients in groups II and III: immunoelectrophoresis, serum IgA, IgG, and IgM concentration (radial immunodiffusion or nephelometry), presence and type of paraproteins, cryoglobulins, rheumatoid factor (Rose-Waaler test), antinuclear antibodies (indirect immunofluorescence on frozen mouse liver sections), anti-SS-A and anti-SS-B (western blotting).

In statistical analyses %κ was used instead of κ/λ ratio as the former looks much more like a normally distributed variable due to the absence of skewness. Student's t test for unpaired observations or the x² test were used to compare histological, immunohistological, and serological parameters, and the clinical course of different groups.

Details of clinical follow up were obtained from the case records of the patients with Sjögren's syndrome.

Results

QUANTITATIVE STUDY

Five quantitative immunohistological parameters are used to quantify the composition of the plasma cellular infiltrates in labial salivary gland tissue. These five parameters are: the mean %IgA, %IgG, %IgM, %κ containing plasma cells and the mean number of light chain containing plasma cells per 0-04 mm² labial salivary gland tissue (κ + λ). These five parameters in patients with RA (group II) were not significantly (p > 0-05) different from those of the group of healthy controls (group I); these five parameters in patients with Sjögren's syndrome (group III) differed significantly from those of healthy controls and patients with RA (table 3). There were no
Table 3  Comparison of quantitative immunohistological results in labial salivary gland tissue of patients and controls

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Group I (n = 80)</th>
<th>Group II (n = 18)</th>
<th>Group III (n = 45)</th>
<th>Primary Sjogren’s syndrome (n = 35)</th>
<th>Secondary Sjogren’s syndrome (n = 10)</th>
</tr>
</thead>
<tbody>
<tr>
<td>%(\kappa)</td>
<td>59.1 (3.4)</td>
<td>59.1 (4.9)</td>
<td>66.7 (9.4)†</td>
<td>66.7 (10.1)</td>
<td>66.9 (10.0)</td>
</tr>
<tr>
<td>%(\kappa + \lambda)</td>
<td>22.0 (10.0)</td>
<td>24.9 (8.1)</td>
<td>80.4 (4.0)†</td>
<td>86.9 (43.1)</td>
<td>56.4 (20.0)‡</td>
</tr>
<tr>
<td>%IgA</td>
<td>88.3 (7.7)</td>
<td>86.4 (9.4)</td>
<td>42.7 (21.2)</td>
<td>43.1 (17.9)</td>
<td>39.1 (14.2)</td>
</tr>
<tr>
<td>%IgG</td>
<td>8.3 (6.0)</td>
<td>8.3 (5.1)</td>
<td>33.6 (13.3)</td>
<td>35.2 (13.7)</td>
<td>27.7 (10.6)</td>
</tr>
<tr>
<td>%IgM</td>
<td>3.4 (3.8)</td>
<td>3.6 (6.1)</td>
<td>24.3 (21.4)</td>
<td>21.7 (21.3)</td>
<td>33.3 (20.2)</td>
</tr>
</tbody>
</table>

%\(\kappa\), %IgA, %IgG, %IgM are percentage of \(\kappa\), IgA, IgG, and IgM containing plasma cells in the labial salivary gland tissue.

†Significantly different from group I and II: \(p < 0.001\), by Student's t test.

‡Significantly different from group I (\(p < 0.001\)) and from group II (\(p = 0.02\)), by Student's t test.

§Significantly different from primary Sjogren's syndrome (\(p = 0.003\)), by Student's t test.

Table 4  Histological, immunohistological and serological results in patients with Sjogren’s syndrome compared with normal (group IIIA) and normal (group IIIB) percentage \(\kappa\) containing plasma cells in labial salivary gland tissue

<table>
<thead>
<tr>
<th>LSG parameter: (Student's t test)</th>
<th>Group IIIA (n = 10)</th>
<th>Group IIIB (n = 35)</th>
<th>(p) Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>%kappa</td>
<td>81.4 (6.2)</td>
<td>62.5 (5.9)</td>
<td>nr</td>
</tr>
<tr>
<td>%IgA</td>
<td>79.1 (32.0)</td>
<td>80.4 (43.6)</td>
<td>0.03</td>
</tr>
<tr>
<td>%IgG</td>
<td>28.4 (14.4)</td>
<td>47.1 (14.5)</td>
<td>0.0001</td>
</tr>
<tr>
<td>%IgM</td>
<td>23.5 (15.4)</td>
<td>36.4 (11.4)</td>
<td>0.005</td>
</tr>
<tr>
<td>%Lymphocytic focus score</td>
<td>51.5 (15.3)</td>
<td>16.5 (11.9)</td>
<td>0.002</td>
</tr>
<tr>
<td>Serum Ig</td>
<td>3.3 (2.1)</td>
<td>3.4 (1.8)</td>
<td>0.006</td>
</tr>
<tr>
<td>IgA (g/l)</td>
<td>2.2 (0.9)</td>
<td>3.3 (1.7)</td>
<td>0.012</td>
</tr>
<tr>
<td>IgG (g/l)</td>
<td>12.4 (5.0)</td>
<td>21.1 (9.4)</td>
<td>0.0005</td>
</tr>
<tr>
<td>IgM (g/l)</td>
<td>2.8 (1.3)</td>
<td>2.2 (1.5)</td>
<td>0.30</td>
</tr>
</tbody>
</table>

%kappa, %IgA, %IgG, %IgM are percentage of \(\kappa\), IgA, IgG, and IgM containing plasma cells in labial salivary gland tissue.

\(\kappa + \lambda\) = total number of \(\kappa\) and \(\lambda\) containing plasma cells per 0.04 mm2 labial salivary gland tissue.

nr = not relevant, as %\(\kappa\) was used to select the two subgroups of Sjogren’s syndrome patients.

Figure 1  Percentages of \(\kappa\) containing plasma cells of all subjects in this study. Dotted horizontal lines define the pooled 99.8% confidence interval (mean ± 3 xSD) of the control groups I and II. Ten patients with Sjogren's syndrome were beyond this confidence interval.

significant differences (\(p > 0.10\)) between primary Sjogren's syndrome and secondary Sjogren's syndrome with regard to %IgA, %IgG, %IgM and %\(\kappa\). In primary Sjogren's syndrome the numerical density of light chain containing plasma cells (\(\kappa + \lambda\)) was significantly higher than in secondary Sjogren's syndrome (\(p = 0.003\)) (table 3).

Figure 1 shows %\(\kappa\) in the labial salivary gland tissue biopsy specimens of all subjects of the three groups. The normal range of %\(\kappa\) (determined in groups I and II and set at the mean ± 3 standard deviations) was 45.9%–72.3%. In 10 patients with Sjogren's syndrome %\(\kappa\) was out of the normal range (fig 1). All these patients had an excess of \(\kappa\) containing plasma cells, with at least 75-5% \(\kappa\) containing plasma cells in the labial salivary gland tissue range %\(\kappa\): 75.5%–91.1%). A %\(\kappa\) of >75 was found in eight of 35 patients with primary Sjogren's syndrome and in two of 10 with secondary Sjogren's syndrome. The difference in prevalence of %\(\kappa\) of ≥75 between primary Sjogren's syndrome and secondary Sjogren's syndrome was not significant (\(p = 0.8\)). The population of patients with Sjogren's syndrome (group III) were divided in two subpopulations, group IIIA with %\(\kappa\) of ≥75 and group IIIB with %\(\kappa\) of <75.

Table 4 shows that patients with abnormal %\(\kappa\) also had significantly higher %IgM (\(p = 0.002\)), significantly lower %IgA and %IgG (\(p < 0.005\)), and a significantly higher lymphocytic focus score (\(p = 0.006\)). There was no significant difference (\(p = 0.93\)) between these two subgroups of Sjogren's syndrome with regard to the total numerical density of plasma cells (\(\kappa + \lambda\)) in the labial salivary gland tissue (table 4). The relation between high percentages of \(\kappa\) and IgM containing plasma cells is clearly shown in the scatter diagram of fig 2.

Table 4 shows that the serum IgA and IgG concentrations in the patients with Sjogren's syndrome of group IIIA were significantly lower than in the patients in group IIIB, with P values of 0.01 and 0.0005, respectively. Fur-
thermore, polyclonal cryoglobulinemia was found significantly more often in patients with Sjögren's syndrome of group IIIA (p = 0.003). The prevalence of normal serum IgG titres (IgG < 13·3 g/l) was significantly higher in group IIIA than in group IIIB patients (p = 0.03).

The scatter diagram in fig 3 shows that all patients with Sjögren's syndrome with %kappa of ≥75 (group IIIA) were older than 43 years. Under the assumption that there is no age predominance for this phenomenon one would expect that four of the 18 patients with Sjögren's syndrome younger than 43 years would have a %kappa of ≥75. Group IIIB patients had the same age distribution as group IIIA patients, but in the former group none of the patients had abnormal %kappa values, despite the presence of lymphocytic adenitis in 89% of them (table 5).

QUALITATIVE STUDY
In the 10 patients with Sjögren's syndrome with %kappa of ≥75 (group IIIA) the results of immunoperoxidase staining of the labial salivary gland tissue biopsy specimens gave rise to suspicion of monotypic plasma cell populations within the infiltrate. In eight of these patients %kappa containing plasma cells predominated throughout all the glands of the biopsy specimen.

In one patient the biopsy specimen, comprising four glands, had a predominance of IgG/kappa containing plasma cells in two glands; in the other two glands there was no suspicion of monotypic plasma cells. In another patient the biopsy specimen, consisting of nine glands, showed predominance of IgA/kappa containing plasma cells in one gland and predominance of IgM/kappa containing plasma cells in the other glands.

In seven of the 10 patients with Sjögren's syndrome with %kappa of ≥75 the labial salivary gland tissue was available for double immunofluorescence labelling. This confirmed the presence of monotypic plasma cell populations within the infiltrate in all seven cases. In six cases the monotypic plasma cell populations were of IgM/kappa type and in one case of both IgM/kappa and IgA/kappa (table 6). Serological, histological, and immunohistological findings of the 10 patients with Sjögren's syndrome with an abnormal %kappa in the labial salivary gland tissue are also shown in table 6.

FOLLOW UP STUDY
Two of the 10 patients with Sjögren's syndrome with an excess of kappa containing plasma cells in the labial salivary gland tissue developed systemic monoclonal gammapathy with circulating IgM/kappa six months and six years, respectively, after the labial salivary gland tissue biopsy had been performed (cases 6 and 10 in table 6). In both cases the circulating paraprotein was identical with that of the immunoglobulin found in the labial salivary gland tissue. In one of these patients Bence Jones (kappa) protein was also found in the urine (case 2 in table 6). In a third patient (case 10 in table 6), with an excess of k containing plasma cells in the labial salivary gland tissue, malignant lymphoma (polymorphic immunocytoma, IgM/kappa) of the lung was diagnosed one year after the labial salivary gland tissue biopsy. In this patient, however, monotypic IgG/kappa B cell expansion in the labial salivary gland tissue was suspected on the basis of the immunoperoxidase staining results. All three patients had primary Sjögren's syndrome.

The median follow up period in the group of 10 patients with Sjögren's syndrome with an abnormal %kappa in the labial salivary gland tissue was three years (range 1·5–9·5 years). None of the patients with normal %kappa in the labial salivary gland tissue had developed systemic monoclonal gammapathy or malignant lymphoma after a median follow up period of 4·5 years (range 1–11 years). In the group of patients with Sjögren's syndrome with %kappa of ≥75% the disease progressed into a systemic monoclonal process or malignant lymphoma significantly more often (p = 0·008).

**Discussion**
This study shows, for the first time, the occurrence of high percentages of kappa light chain containing plasma cells, due to the presence of monotypic plasma cell populations, in the labial salivary gland tissue of 10 of our 45 (22%) patients with Sjögren's syndrome but without evidence of systemic monoclonal lymphoproliferative disease at the time of labial

![Figure 3 Scatter diagram of % containing plasma cells compared with age of all subjects in this study.](http://jcp.bmj.com/)

<table>
<thead>
<tr>
<th>Table 5</th>
<th>Mean ages and percentage of kappa containing plasma cells in labial salivary gland tissue in all patients and controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group</td>
<td>N</td>
</tr>
<tr>
<td>I (Healthy controls)</td>
<td>80</td>
</tr>
<tr>
<td>II (RA)</td>
<td>18</td>
</tr>
<tr>
<td>I + II</td>
<td>98</td>
</tr>
<tr>
<td>III (SS, %kappa &gt;75)</td>
<td>10</td>
</tr>
<tr>
<td>III (SS, %kappa &lt;75)</td>
<td>35</td>
</tr>
<tr>
<td>III (SS, whole group)</td>
<td>45</td>
</tr>
</tbody>
</table>

RA = rheumatoid arthritis; SS = Sjögren's syndrome; %kappa = percentage of kappa containing plasma cells in labial salivary gland tissue.
salivary gland tissue biopsy. Although systemic lymphoproliferative disorders are sometimes considered to be related to primary Sjögren’s syndrome, this could not be validated. Of special clinical interest is our observation that progression into systemic monoclonal gammopathy or malignant lymphoma exclusively occurred in the subgroup of patients with Sjögren’s syndrome with monotypic plasma cell populations, defined by a $\kappa/\lambda$ ratio of $\geq 3$.

Our findings agree with those obtained from immunohistological studies of the benign lymphoepithelial lesion of the major salivary glands, which is closely related to Sjögren’s syndrome. These studies showed that extra-salivary lymphoma occurred exclusively in patients with a benign lymphoepithelial lesion with monotypic proliferation areas and not in those with polytypic proliferation areas. A report of myoepithelial sialadenitis (benign lymphoepithelial lesion) of the major salivary glands with proliferations of B cells with monotypic cytoplasmatic immunoglobulins has been considered to be a neoplastic lesion, and monotypic areas of the group with Sjögren’s syndrome with monotypic plasma cell populations (group IIIA). However, none of these patients with RA had a $\%K$ of $\geq 75$, but about 50% of these patients had lymphocytic adenitis with a focus score of $>1$, mimicking the sialadenitis of Sjögren’s syndrome.

The monoclonal origin of the monotypic plasma cells in autoimmune sialadenitis has been confirmed by immunoglobulin gene rearrangement studies. Fishleder et al found in benign lymphoepithelial lesions of parotid and submandibular gland, removed two years later from the same patient with Sjögren’s syndrome, that the rearrangements of the heavy chain and $\kappa$ light chain genes were entirely different, making it highly unlikely that the B cell clone identified in the second lesion evolved from the first. Different immunoglobulin gene rearrangements in the same patient with benign lymphoepithelial lesions of different major salivary glands have also been observed by Freemark et al. We did not perform immunoglobulin gene rearrangement studies due to shortage of tissue. However, our observation that multiple separated minor salivary glands of a labial salivary gland tissue biopsy specimen are populated by monotypic plasma cells of the same isotype (IgM/$\kappa$) or even of different isotypes in different glands in one of our patients (IgM/$\kappa$ and IgA/$\lambda$) supports the hypothesis that monoclonal plasma cell populations in the salivary glands of patients with Sjögren’s syndrome are not the result of a clonal expansion of a single neoplastic changed lymphoid stem cell. Our observation of equal mean total numbers of $\kappa$ and $\lambda$ containing plasma cells per 0.04 mm$^2$ of salivary gland tissue in the two groups of patients with Sjögren’s syndrome also argues against the assumption of neoplastic B cell proliferation in patients with monotypic plasma cell populations. More convincing support can be found in our observation that an IgM/$\lambda$ polytypic immunocytoma of the lung developed in a patient with Sjögren’s syndrome and with predominance of IgG/$\kappa$ containing plasma cells in the labial salivary gland tissue.

In our study all subjects with $\%K$ of $\geq 75$ were patients with Sjögren’s syndrome and older than 43 years. If there was no age preference for the occurrence of monotypic plasma cell infiltrates in patients with Sjögren’s syndrome one could expect that four of our 18 patients younger than 43 years would also exhibit this phenomenon. In group II (patients with RA) the age distribution pattern of the monoclonal groups with Sjögren’s syndrome with monotypic plasma cell populations (group IIIA). However, none of these patients with RA had a $\%K$ of $\geq 75$, but about 50% of these patients had lymphocytic adenitis with a focus score of $>1$, mimicking the sialadenitis of Sjögren’s syndrome.

All aforementioned observations support the hypothesis that monotypic plasma cell populations appear after a latency period in the labial salivary gland tissue and probably also in other exocrine glands in some patients with Sjögren’s syndrome and with an initial polytypic plasma cellular infiltrate. This switch from a polytypic to a monotypic plasma cell infiltrate in many different glands cannot be attributed to neoplastic changes. A more likely explanation is that the exocrine glands in a subpopulation of patients with Sjögren’s syndrome are homed by primitive B cells, which are liable to homeostatically regulated clonal expansions after prolonged antigenic stimulation by modified parenchymal cells in the target organs, and that this phenomenon is accompanied by an increased risk to develop systemic monoclonal lymphoproliferative disorders. On the basis of several studies B

---

Table 6 Serological and immunohistopathological results of group IIIA

| Case No | Age (years) | ANA | RF | a-SS-A | a-SS-B | Cryo | IgA ($g/l$) | IgG ($g/l$) | IgM ($g/l$) | $%K$ | $%IgA$ | $%IgG$ | $%IgM$ | LFS | Monotypic Ig (double IF)
|---------|-------------|-----|----|--------|--------|------|-------------|-------------|-------------| -----|--------|--------|--------|-----|------------------|
| 1       | 50          | +   | +  | +      | +      | +    | 1.7         | 12.5        | 4.7         | 80.7 | 37.7   | 29.2   | 33.1   | 2.6 | IgA$\kappa$ and IgM$\lambda$
| 2       | 73          | -   | -  | +      | -      | +    | 1.5         | 7.0         | 4.0         | 91.1 | 7.0    | 8.0    | 85.0   | 8.4 | IgM$\lambda$
| 3       | 62          | +   | -  | +      | -      | +    | 1.0         | 5.6         | 3.7         | 86.3 | 16.4   | 4.2    | 79.4   | 7.9 | IgM$\lambda$
| 4       | 59          | -   | ND | +      | +      | +    | 3.1         | 21.8        | 1.7         | 91.9 | 3.8    | 32.2   | 64.1   | 7.4 | IgM$\lambda$
| 5       | 55          | -   | -  | -      | -      | +    | 1.4         | 9.4         | 3.6         | 79.3 | 21.9   | 24.2   | 53.9   | 5.3 | IgM$\lambda$
| 6       | 66          | +   | -  | +      | +      | +    | 2.1         | 8.1         | 3.2         | 78.8 | 36.1   | 4.8    | 49.1   | 3.0 | IgM$\lambda$
| 7       | 44          | -   | ND | -      | -      | +    | 1.7         | 17.7        | 2.3         | 76.2 | 32.3   | 24.7   | 43.1   | 4.7 | IgM$\lambda$
| 8       | 69          | +   | +  | +      | -      | -    | 2.7         | 13.7        | 6.6         | 75.5 | 50.2   | 44.2   | 5.5    | 3.7 | ND
| 9       | 69          | +   | +  | +      | -      | -    | 3.0         | 12.4        | 1.2         | 78.9 | 18.4   | 9.7    | 75.9   | 6.0 | ND
| 10      | 71          | -   | ND | -      | -      | +    | 3.7         | 15.3        | 2.9         | 75.7 | 24.7   | 47.7   | 27.6   | 4.0 | ND

ANA = antinuclear antibody; RF = rheumatoid factor; a-SS-A = antibodies against SS-A; a-SS-B = antibodies against SS-B; Cryo = cryoglobulinaemia; $%K$, $%IgA$, $%IgG$, $%IgM$ = percentages of $K$, IgA, IgG, and IgM containing plasma cells; LFS = lymphocytic focus score; monotypic Ig = monoclonal immunoglobulin; Double IF = double immunofluorescence labelling; ND = not done; Normal values are: IgA 0.3–2.5 g/l, IgG 4.7–15.3 g/l, IgM 0.4–2.4 g/l. Cases 2 and 7 had secondary Sjögren’s syndrome.
lymphocytes expressing CD5 antigen which are related to autoantibody production and monoclonal expansions, are a serious candidate.

In summary, the results of the present study and those of Schmid et al. show that patients with Sjögren’s syndrome and monoclonal B cell populations in their salivary glands are at increased risk of developing systemic monoclonal lymphoproliferative disorders. Knowing that the relative risk of all patients with Sjögren’s syndrome of developing malignant lymphoma is about 44 times higher than in the normal population, it can be assumed that the relative risk of the subgroup of such patients with monoclonal B cell populations in their salivary glands is considerably higher. We conclude that quantitative immunohistological examination of labial salivary gland tissue provides pathologists with a simple method to select those patients with an increased relative risk, at the time of labial salivary gland tissue biopsy of developing benign or malignant lymphoproliferative disorders.

This study was financially supported by a grant (88/CR/104/90) from the Dutch League against Rheumatism (Het Nationaal ReumaFonds).